Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CAMA-1 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 2.67 | uM | 14897.203 | 0.0295 | -0.9517 | 0.9464 | |
| CAMA-1 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 2.67 | uM | 14897.203 | 0.0295 | -0.9517 | 0.9464 | |
| CAMA-1 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 13.3 | uM | 14897.203 | 0.0139 | -0.9782 | 0.9464 | |
| CAMA-1 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 13.3 | uM | 14897.203 | 0.0139 | -0.9782 | 0.9464 | |
| CAMA-1 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 14897.203 | 0.0124 | -0.9807 | 0.9464 | |
| CAMA-1 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 14897.203 | 0.0124 | -0.9807 | 0.9464 | |
| EFM-19 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.000171 | uM | 15296.203 | 1.1021 | 1.1812 | 1.1208 | |
| EFM-19 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.000171 | uM | 15296.203 | 1.1021 | 1.1812 | 1.1208 | |
| EFM-19 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.000853 | uM | 15296.203 | 1.0620 | 1.1103 | 1.1208 | |
| EFM-19 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.000853 | uM | 15296.203 | 1.0620 | 1.1103 | 1.1208 | |
| EFM-19 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.00427 | uM | 15296.203 | 0.6668 | 0.3931 | 1.1208 | |
| EFM-19 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.00427 | uM | 15296.203 | 0.6668 | 0.3931 | 1.1208 | |
| EFM-19 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0213 | uM | 15296.203 | 0.1170 | -0.7051 | 1.1208 | |
| EFM-19 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0213 | uM | 15296.203 | 0.1170 | -0.7051 | 1.1208 | |
| EFM-19 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.107 | uM | 15296.203 | 0.0569 | -0.8451 | 1.1208 | |
| EFM-19 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.107 | uM | 15296.203 | 0.0569 | -0.8451 | 1.1208 | |
| EFM-19 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.533 | uM | 15296.203 | 0.0472 | -0.8689 | 1.1208 | |
| EFM-19 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.533 | uM | 15296.203 | 0.0472 | -0.8689 | 1.1208 | |
| EFM-19 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 2.67 | uM | 15296.203 | 0.0199 | -0.9394 | 1.1208 | |
| EFM-19 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 2.67 | uM | 15296.203 | 0.0199 | -0.9394 | 1.1208 | |
| EFM-19 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 13.3 | uM | 15296.203 | 0.0239 | -0.9285 | 1.1208 | |
| EFM-19 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 13.3 | uM | 15296.203 | 0.0239 | -0.9285 | 1.1208 | |
| EFM-19 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 15296.203 | 0.0266 | -0.9214 | 1.1208 | |
| EFM-19 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 15296.203 | 0.0266 | -0.9214 | 1.1208 | |
| EFM-192A | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.000171 | uM | 15284.203 | 1.0045 | 1.0129 | 0.6980 |